← back to search

Geoff Macintyre

Centro Nacional de Investigaciones Científicas · ES
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Prostate Cancer Treatment and Research, Genomics and Phylogenetic Studies, and Ovarian cancer diagnosis and treatment.
h-index
50
citations
22,297
works
158
NIH funding
primary concept
Biology
email

Recent publications

WNT-driven chromosomal instability as a biomarker for PORCN inhibition
2026cited by 0position: contributordoi
Predicting resistance to chemotherapy using chromosomal instability signatures
Nature Genetics 2025cited by 14position: lastdoi
Predicting resistance to chemotherapy using chromosomal instability signatures.
2025cited by 8position: contributordoi
A comprehensive genetic catalog of human double-strand break repair.
2025cited by 2position: contributordoi
Tracking ongoing chromosomal instability using single-cell whole-genome sequencing
2025cited by 2position: contributordoi
Inherited genome instability.
2025cited by 1position: contributordoi
Forecasting oncogene amplification and tumour suppressor deletion
2025cited by 1position: contributordoi
scAbsolute: measuring single-cell ploidy and replication status
Genome biology 2024cited by 13position: middledoi
A comprehensive genetic catalog of human double-strand break repair
2024cited by 2position: contributordoi
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
2023cited by 57position: contributordoi
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
2023cited by 49position: contributordoi
High-grade serous ovarian carcinoma organoids as models of chromosomal instability
eLife 2023cited by 31position: middledoi
Predicting response to cytotoxic chemotherapy
bioRxiv (Cold Spring Harbor Laboratory) 2023cited by 2position: lastdoi
Pan-cancer evolution signatures link clonal expansion to dynamic changes in the tumour immune microenvironment
bioRxiv (Cold Spring Harbor Laboratory) 2023cited by 2position: middledoi
Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
2023cited by 2position: contributordoi
Predicting response to cytotoxic chemotherapy
2023cited by 2position: contributordoi
Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer
Nature Genetics 2023cited by 1position: middledoi
Author response: High-grade serous ovarian carcinoma organoids as models of chromosomal instability
2023cited by 0position: middledoi
Pan-cancer evolution signatures link clonal expansion to dynamic changes in the tumour immune microenvironment
2023cited by 0position: contributordoi
A medley of resistance in ovarian cancers.
2023cited by 0position: contributordoi
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Supplementary Data from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Data from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Florian Markowetz · University of Cambridge57 papers (2016–2026) · 55 papers (2020–2026) · 46 papers (2020–2026)James D. Brenton · University of Manchester46 papers (2020–2026)Lena Morrill Gavarró · Cancer Research UK Cambridge Center41 papers (2020–2023)Philip S. Smith · Cancer Research UK Cambridge Center39 papers (2021–2023)Michelle Lockley · Genomics England38 papers (2021–2023)Iain A. McNeish · Imperial College London38 papers (2021–2023)Thomas Bradley · University of Cambridge38 papers (2021–2023)Hasan B. Mirza · Barts Health NHS Trust37 papers (2022–2023)Zhao Cheng · University of Cambridge36 papers (2021–2023)James D. Brenton · University of Cambridge8 papers (2018–2024)Anna Piskorz · University of Cambridge7 papers (2018–2024)Barbara Hernando · Spanish National Cancer Research Centre7 papers (2021–2026)Carolin Margarethe Sauer · Cancer Research UK Cambridge Center5 papers (2021–2025)Ke Yuan · Shenzhen Maternity and Child Healthcare Hospital5 papers (2017–2023)Michael P Schneider · University of Cambridge5 papers (2022–2024)Ángel Fernández-Sanromán · Spanish National Cancer Research Centre4 papers (2024–2025)Blas Chaves-Urbano · Spanish National Cancer Research Centre4 papers (2021–2025) · 4 papers (2022–2023)